Dothiepin

Tricyclic antidepressant

Identification
Generic Name
Dothiepin
Brand Name

 
Attributes
Pregnancy
C

Indication
Condition Contra-Indication
Benign Prostatic Hypertrophy
Suicidal Behavior
Angle Closure Glaucoma
Epilepsy: Absence Seizure
Epilepsy: Atonic Generalized Seizure
Epilepsy: Complex Partial Seizure
Epilepsy: Generalized Tonic Clonic Seizure
Epilepsy: Myoclonic Generalized Seizure
Epilepsy: Simple Partial Seizure
Epilepsy: Tonic Generalized Seizure
Febrile Seizures
Glaucoma
Diabetes Mellitus
Diabetes Type 1
Diabetes Type 2
Congenital Erythropoietic Porphyria
Acute Porphyrias
Dual Porphyria
Acute Intermittent Porphyria
Hepatoerythropoietic Porphyria

 
Other Contra-Indication
Our Records are Incomplete for Other Contra-Indications

Contra-Indication

 
Class Contra-Indication
Our Records are Incomplete for Drug Class Contra-Indications

Side Effects
Common
Drowsiness
Mouth Dry (Xerostomia)
Vision Blurred
Constipation
Weight Gain (Body Mass Index Raised)
Mind: Delirium
Dizziness
Sweating (Perspiring)
Involuntary Trembling Or Quivering (Tremor)
Mind: Agitation
Insomnia
Urinary Retention (Ischuria)
Uncommon
Heart Rate Irregular (Arrhythmia)
Blood Glucose Levels High or Increased (Hyperglycaemia, Hyperglycemia)
Breast Enlargement in Males (Gynaecomastia)
Breast Milk Abnormal Secretions From Nipple (Galactorrhoea)
Nausea
Rare

Dothiepin

 

Dosulepin hydrochloride (INN) (formerly the BAN dothiepin hydrochloride) is an antidepressant of the tricyclic family. It is sold under the brand names Prothiaden, Dothep, Thaden and Dopress. Dosulepin works by preventing serotonin and noradrenaline from being reabsorbed in the brain. This helps prolong the mood lightening effect of any released noradrenaline and serotonin, thus relieving depression.

Indications

Dosulepin is relatively mild and is used for low-level anxiety, depression and similar disorders, as well as the treatment of chronic and ongoing pain disorders, particularly where insomnia and/or loss of appetite are present. It can take between two and four weeks of regular usage to become effective; it is often started at a low level and the dosage increased if this is ineffective. The drug causes drowsiness as a side-effect, and this may be used as part of the treatment, since anxiety-depressive patients may have difficulty sleeping; it can also be combined with other drugs such as temazepam.

Dosage

Adults: Initially 75 mg/day in divided doses or as a single dose at night, increasing to 150 mg/day. In certain circumstances, e.g. in hospital use or unresponsive patients, dosages up to 300 mg daily have been used.

Suggested regimens: 25 or 50 mg three times daily or, alternatively, 75 or 150 mg as a single dose at night. Should the regimen of 150 mg as a single night-time dose be adopted, it is better to give a smaller dose for the first few days.

Elderly: 50 to 75 mg daily initially. As with any antidepressant, the initial dose should be increased with caution under close supervision. Half the normal adult dose may be sufficient to produce a satisfactory clinical response.

Children: Not recommended. [1]

Side effects

The most common side-effects are drowsiness and dry mouth as well as dry eyes. Other less common side-effects may include:

These side-effects cease when treatment ceases. Alcohol should be avoided whilst taking dosulepin as it may increase some side-effects.

Whilst dosulepin is not addictive, it should not be stopped suddenly as there is a risk of initial withdrawal symptoms which may be mistaken for some of the original indications for the drug:

  • Nausea
  • Vomiting
  • Loss of appetite
  • Headache
  • Giddiness
  • Chills
  • Insomnia
  • Anxiety

Contra-indications

Contra-indications include:

Drug interactions

The drug can interact dangerously with vasoconstrictors and should not be taken in combination with phenylephrine or adrenaline in particular.

The sedative effects of other CNS depressants (benzodiazepines such as diazepam and lorazepam, sedative antihistamines, opiates, etc.) may be increased.

This drug should not be started within 2 weeks of stopping a monoamine oxidase inhibitor (MAOI) antidepressant, and should not be co-administered with any selective serotonin reuptake inhibitor (SSRI) antidepressant such as fluoxetine), or any medication which affects the electrical impulses to the heart (e.g. astemizole, halofantrine or terfenadine).

The drug is not recommended for use by children nor to be taken in combination with some other drugs, including herbal remedies.

Overdose

The symptoms and the treatment of an overdose are largely the same as for the other tricyclic antidepressants.

References

See also

 

GT:0.069